Welcome to our dedicated page for Arbutus Biopharma SEC filings (Ticker: ABUS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Arbutus Biopharma's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Arbutus Biopharma's regulatory disclosures and financial reporting.
Arbutus Biopharma Corp (ABUS) is the subject of a Schedule 13G filed by a group of Whitefort Capital entities and individuals David Salanic and Joseph Kaplan. As of September 4, 2026, the group reports beneficial ownership of 15,794,261 common shares, representing approximately 8.0% of Arbutus’s outstanding common shares, based on 198,105,743 shares outstanding as of August 19, 2026. The shares are held with shared voting and dispositive power through Whitefort Capital Master Fund, LP, with related general partners and managers "deemed" beneficial owners. The filers state they no longer hold the securities with a purpose or effect of changing or influencing control of Arbutus and therefore report on Schedule 13G in accordance with Rule 13d-1(h).
Arbutus Biopharma Corporation (ABUS) has launched an issuer tender offer to repurchase for cash up to US$230 million in value of its common shares. The offer is made on the terms set out in an Offer to Purchase and accompanying Issuer Bid Circular and related Letter of Transmittal.
As of August 19, 2026, 198,105,743 common shares were issued and outstanding; this is a baseline figure, not the amount being sought in the offer. The company states that it will fund purchases of shares, including related fees and expenses, from available cash on hand, and that the consideration consists solely of cash.
Arbutus Biopharma Corp (ABUS) announced plans to launch a modified “Dutch auction” issuer tender offer to repurchase up to US$230 million of its common shares. Shareholders will be able to tender shares within a price range of US$5.00 to US$5.75 per share.
The company stated that the tender offer has not yet commenced and may not proceed on these terms or at all. Upon commencement, Arbutus will file a Schedule TO with U.S. and Canadian regulators, and the offer will be made only through the formal offer to purchase, issuer bid circular, letter of transmittal and related documents.
Arbutus Biopharma Corporation (ABUS) announced plans to launch a modified “Dutch auction” tender offer to repurchase up to US$230 million of its common shares. The company expects to offer shareholders the opportunity to tender shares within a price range of US$5.00 to US$5.75 per share.
The offer is expected to commence on or about August 24, 2026 and, unless extended or terminated, expire on or about September 29, 2026. It is expected to be funded using the company’s cash on hand, including proceeds associated with a March 2026 settlement with Moderna and an initial payment received in July 2026.
Arbutus states that the offer has not yet commenced and is subject to obtaining certain exemptive relief under U.S. and Canadian securities laws, including for a proportionate tender feature and certain extension requirements. The company plans to file a Schedule TO and related offer documents when the tender offer begins.
Morgan Stanley and Morgan Stanley Investment Management Inc. report significant beneficial ownership positions in Arbutus Biopharma Corp common shares. As of June 30, 2026, certain Morgan Stanley reporting units beneficially own 17,387,398 Arbutus common shares, representing 8.8% of the class, all with shared voting and dispositive power and no sole power.
Morgan Stanley Investment Management Inc. separately reports beneficial ownership of 17,122,142 Arbutus common shares, representing 8.7% of the class, also entirely with shared voting and dispositive power. The filing notes that it covers only specified Morgan Stanley reporting units and may exclude other units whose holdings are disaggregated under SEC Release No. 34-39538.
Arbutus Biopharma reported a sharp improvement in results for the six months ended June 30, 2026, driven by litigation-related license income. Total revenue was $180.1 million, up from $12.5 million a year earlier, primarily from $179.4 million of license revenue from Genevant, which includes Arbutus’ $178.4 million share of a $950.0 million noncontingent settlement payment from Moderna.
Operating expenses fell to $17.2 million from $36.7 million, reflecting prior restructuring and lower R&D. Arbutus generated net income of $164.6 million versus a $22.0 million loss in the prior-year period, although it recorded a $5.1 million net loss in the second quarter alone as settlement revenue was recognized earlier in the year. At June 30, 2026, the company held $92.6 million in cash, cash equivalents and short-term marketable securities with no debt, and also received the $178.4 million cash settlement on July 8, 2026. Management states it has sufficient resources to fund operations for at least the next 12 months while advancing hepatitis B programs, including imdusiran, which received FDA Fast Track designation, and AB‑101.
Arbutus Biopharma reported second quarter 2026 revenue of $1.0 million, down sharply from $10.7 million a year earlier, and a net loss of $5.1 million versus net income of $2.5 million in the prior-year quarter, driven largely by the absence of one-time deferred revenue recognized in 2025.
Despite the quarterly loss, Arbutus highlighted a significantly stronger balance sheet. As of June 30, 2026, it held $92.6 million in cash, cash equivalents and marketable securities and recorded a $179.4 million receivable from its Genevant license, reflecting its share of a $950 million global settlement with Moderna, including a $178.4 million noncontingent payment received in July and a further $1.3 billion potential contingent payment tied to appellate outcomes. The company stated it expects, subject to board approval, to return up to approximately $230 million to shareholders beginning in the third quarter of 2026 through possible share repurchases. Research and development expenses fell to $2.9 million from $5.5 million due to prior restructuring, while general and administrative costs rose to $3.9 million. Arbutus also reported FDA Fast Track designation and Phase 2b trial design alignment for its HBV candidate imdusiran and disclosed new international patent enforcement lawsuits filed with Genevant against Pfizer and BioNTech relating to lipid nanoparticle technology.
Arbutus Biopharma detailed several outcomes from its mRNA patent disputes. A March 2026 settlement with Moderna generated a $950 million noncontingent lump sum to Arbutus and Genevant, of which Arbutus received about $178 million (including reimbursed litigation costs), and provides for a potential contingent payment of up to $1.3 billion. Arbutus also terminated a prior RSV-related sharing agreement with Genevant in exchange for a $1.0 million termination fee.
The board approved one-time litigation-related cash bonuses for the CEO and for the CFO, whose bonus equals 0.25% of proceeds tied to the Moderna settlement. Arbutus and Genevant filed three international patent lawsuits against Pfizer/BioNTech over lipid nanoparticle technology, seeking monetary relief and injunctions. Arbutus expects to return capital to shareholders through repurchases of up to approximately $230 million of common shares after an anticipated dividend from its approximately 16% equity stake in Genevant’s parent, though any repurchase remains subject to board approval and may not occur.
Arbutus Biopharma Corp director Roger Sawhney received a fully vested stock option grant covering 78,800 common shares. The option was granted at an exercise price of $4.24 per share, matching the closing price of the company’s common shares on Nasdaq on the grant date.
The option is immediately exercisable and expires on June 8, 2036. This transaction reflects an equity-based compensation award and does not involve any open-market purchase or sale of Arbutus Biopharma shares.
Arbutus Biopharma director Robert A. Beardsley was granted stock options to acquire 78,800 common shares. The options have an exercise price of $4.24 per share, are fully vested and exercisable as of the grant date, and expire on June 8, 2036. This is a compensation-related award, not an open-market purchase or sale.